426 related articles for article (PubMed ID: 21470343)
1. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
Morikawa K; Lange CM; Gouttenoire J; Meylan E; Brass V; Penin F; Moradpour D
J Viral Hepat; 2011 May; 18(5):305-15. PubMed ID: 21470343
[TBL] [Abstract][Full Text] [Related]
2. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
[TBL] [Abstract][Full Text] [Related]
3. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.
Johnson CL; Owen DM; Gale M
J Biol Chem; 2007 Apr; 282(14):10792-803. PubMed ID: 17289677
[TBL] [Abstract][Full Text] [Related]
4. Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0.
Horner SM; Park HS; Gale M
J Virol; 2012 Mar; 86(6):3112-20. PubMed ID: 22238314
[TBL] [Abstract][Full Text] [Related]
5. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.
White PW; Llinas-Brunet M; Bös M
Prog Med Chem; 2006; 44():65-107. PubMed ID: 16697895
[No Abstract] [Full Text] [Related]
6. Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase.
Shiryaev SA; Cheltsov AV; Strongin AY
PLoS One; 2012; 7(7):e40029. PubMed ID: 22768327
[TBL] [Abstract][Full Text] [Related]
7. Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.
Brenndörfer ED; Brass A; Karthe J; Ahlén G; Bode JG; Sällberg M
J Immunol; 2014 Feb; 192(4):1671-80. PubMed ID: 24442435
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.
Welsch C; Haselow K; Gouttenoire J; Schneider M; Morikawa K; Martinez Y; Susser S; Sarrazin C; Zeuzem S; Antes I; Moradpour D; Lange CM
J Hepatol; 2015 Apr; 62(4):779-84. PubMed ID: 25463536
[TBL] [Abstract][Full Text] [Related]
9. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
Chen SH; Tan SL
Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
[TBL] [Abstract][Full Text] [Related]
10. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
11. Resistance mutations against HCV protease inhibitors and antiviral drug design.
Shang L; Lin K; Yin Z
Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
[TBL] [Abstract][Full Text] [Related]
12. Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission.
Anggakusuma ; Brown RJP; Banda DH; Todt D; Vieyres G; Steinmann E; Pietschmann T
J Virol; 2016 Dec; 90(23):10670-10681. PubMed ID: 27654291
[TBL] [Abstract][Full Text] [Related]
13. In trans interaction of hepatitis C virus helicase domains mediates protease activity critical for internal NS3 cleavage and cell transformation.
Pan RY; Hung TM; Kou YH; Chan NL; Chang MF; Chang SC
FEBS Lett; 2010 Feb; 584(3):482-6. PubMed ID: 19958771
[TBL] [Abstract][Full Text] [Related]
14. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.
Dultz G; Shimakami T; Schneider M; Murai K; Yamane D; Marion A; Zeitler TM; Stross C; Grimm C; Richter RM; Bäumer K; Yi M; Biondi RM; Zeuzem S; Tampé R; Antes I; Lange CM; Welsch C
J Biol Chem; 2020 Oct; 295(40):13862-13874. PubMed ID: 32747444
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus NS3/4A protease.
Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
[TBL] [Abstract][Full Text] [Related]
16. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
Vazquez C; Tan CY; Horner SM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
[TBL] [Abstract][Full Text] [Related]
18. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
[TBL] [Abstract][Full Text] [Related]
19. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
